Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05548803 · ClinicalTrials.gov registry record

COVID-19 Citizen Science Expansion Project

A clinical trial of COVID-19, sponsored by University of California, San Francisco.

Completed
Registry status
54,689
Enrollment target
9
Study locations

NCT05548803: Completed study of COVID-19, sponsored by University of California, San Francisco.

NCT05548803 is a study of COVID-19 that has completed, run by University of California, San Francisco. The registered enrollment target is 54,689 participants, above the 38,281-participant average among 298 other COVID-19 trials with a reported enrollment target (43% higher). The trial reports 9 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05548803, a study of COVID-19, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
54,689 participants
Enrollment target
9
Study locations

Study Summary

COVID-19 Citizen Science (CCS), launched in March 2020, supports collaborative research on symptoms, risk factors, surveillance, biomarkers and testing for COVID-19 using the Eureka Research Platform. CCS maintains IRB approval with UCSF's IRB (UCSF IRB# 17-21879). This CCS Expansion Project, which is funded jointly by the National Institutes of Health (NIH), the Patient-Centered Outcomes Research Institute (PCORI), and the Bill and Melinda Gates Foundation, will invite patients at health systems across the US to contribute their health records data and then join the established CCS study, allows for linked analysis of CCS data and health records data, and provides the scientific rationale and plan for the project.

Primary Outcome

Anxiety is measured in monthly surveys using the seven-item General Anxiety Disorder-7 (GAD-7) questionnaire. Responses to each item in the GAD-7 are scored as integer values between 0-3 according to the frequency of symptoms during the preceding two weeks ("Not at all", "Several days", "More than half the days", or "Nearly every day"). The sum of all seven items produces a combined score between 0-21, where scores ≥ 10 are considered indicative of moderate to severe anxiety disorders

Conditions Studied

Study Locations (9)

New York

  • NYC Health + Hospitals - New York
  • New York University - New York
  • Albert Einstein College of Medicine - The Bronx

California

  • Sutter Health - Sacramento
  • University of California, San Francisco - San Francisco

Illinois

  • Advocate Aurora Health - Downers Grove

Louisiana

  • Ochsner Health System - New Orleans

Texas

  • Baylor Scott and White Health - Dallas

Utah

  • University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 54,689 participants
Start Date 2020-11-24
Est. Completion 2024-09-01

What the finished NCT05548803 record still lists

NCT05548803 is an observational study that tracks outcomes without assigning an intervention. Its 54,689 participants enrollment target places it among the larger protocols in the corpus, above the 38,281-participant average among 298 other COVID-19 trials with a reported enrollment target (43% higher).

The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 0 interventions.

NCT05548803 lists 9 locations in 6 states (New York, California, Illinois).

Frequently Asked Questions

What is clinical trial NCT05548803 about?

NCT05548803 is a clinical study titled "COVID-19 Citizen Science Expansion Project". COVID-19 Citizen Science (CCS), launched in March 2020, supports collaborative research on symptoms, risk factors, surveillance, biomarkers and testing for COVID-19 using the Eureka Research Platform. CCS maintains IRB approval with UCSF's IRB (UCSF IRB# 17-21879). This CCS Expansion Project, which...

What is the current status of trial NCT05548803?

This trial is currently completed. The enrollment target is 54,689 participants. The study started on 2020-11-24. Estimated completion is 2024-09-01.

What conditions does trial NCT05548803 study?

This clinical trial studies the following conditions: COVID-19.

Who is sponsoring clinical trial NCT05548803?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05548803 being conducted?

This trial has 9 study locations across California, Illinois, Louisiana, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05548803's enrollment target sits among peer trials

54,689 6th of 298 higher than 293 of 298 other COVID-19 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT07224243 · 54,000 participants · NA

    Impact of Intraoperative Oxygenation Practices on Patient Outcomes

  • NCT05975671 · 52,500 participants · NA

    Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis

  • NCT06355934 · 52,121 participants

    OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

  • NCT00500123 · 50,000 participants

    The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05548803, the US trial registry maintained by the National Library of Medicine. NCT05548803 (large enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.